Roche
Roche’s Tecentriq falls short as an adjuvant monotherapy in muscle-invasive urothelial cancer
January 24, 2020Medical Communications, Sales and Marketing Cancer, Roche, pharma, tecentriq, trial failure
Roche has released an update on the development of its immunology Tecentriq (atezolizumab), making it known that the drug failed …
Roche’s risdiplam hits main goal in infants with spinal muscular atrophy
January 23, 2020Research and Development Roche, pharma, risdiplam, spinal muscular atrophy
Roche has announced the success of its survival motor neuron-2 (SMN2) splicing modifier risdiplam in a new trial investigating its …
China approves Roche cancer drug Kadcyla
January 22, 2020Business Services China, Roche, breast cancer, cancer treatment, oncology
China has approved the import of Roche’s drug for breast cancer, just after it recently won expanded approval in the …
EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma
January 21, 2020Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma
The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.
Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma
December 16, 2019Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …
Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer
December 12, 2019Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …
Roche’s Tecentriq combo scores FDA approval in non-small cell lung cancer
December 4, 2019Research and Development, Sales and Marketing FDA, NSCLC, Roche, pharma, tecentriq
Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane …
Roche’s satralizumab shows promise at Phase 3 in neuromyelitis optica spectrum disorder
December 2, 2019Research and Development, Sales and Marketing Roche, pharma, satralizumab
Roche has presented new data on its interleukin-6 (IL-6) inhibitor satralizumab in the treatment of neuromyelitis optica spectrum disorder (NMOSD), …
Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma
November 25, 2019Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq
Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
Working Life Interview: Alison Muir, Oncology Product Strategy Director at Roche
November 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, Working Life, feature, pharma
You studied biology at Liverpool John Moores University before heading straight to GSK in 1990 as a Sales Representative; was …
Roche’s risdiplam hits main goal in spinal muscular atrophy type 2 or 3
November 11, 2019Research and Development, Sales and Marketing Roche, pharma, risdiplam, spinal muscular atrophy
Roche has lifted the curtain on new data which shows that its investigational survival motor neuron-2 (SMN2) splicing modifier risdiplam …
Roche terminates Duchenne muscular dystrophy candidate due to poor clinical outlook
November 8, 2019Medical Communications, Research and Development Duchenne Muscular Dystrophy, Roche, pharma
Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent …
Roche’s Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma
October 21, 2019Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq
New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
FDA greenlights Genentech’s Xofluza for acute, uncomplicated influenza
October 18, 2019Medical Communications FDA, Genetech, Roche, US, Xofluza, flu, pharma
Roche subsidiary Genentech has announced that its polymerase acidic endonuclease inhibitor Xofluza (baloxavir marboxil) has been awarded FDA approval in …
Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris
October 14, 2019Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma
Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
